Posts

Posted on

ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit

PR Newswire


NEW YORK
, Nov. 15, 2025 /PRNewswire/ —

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”), of the important December 8, 2025 lead plaintiff deadline.

So what: If you purchased aTyr Pharma common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the aTyr Pharma class action, go to https://rosenlegal.com/submit-form/?case_id=46109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy of Efzofitimod, particularly, the drug’s capability to allow a patient to completely taper their steroid usage.
When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the aTyr Pharma class action, go to https://rosenlegal.com/submit-form/?case_id=46109 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/atyr-investors-have-opportunity-to-lead-atyr-pharma-inc-securities-fraud-lawsuit-302615902.html

SOURCE THE ROSEN LAW FIRM, P. A.

Posted on

NFLX INVESTIGATION: Investigation Launched into Netflix, Inc., Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

PR Newswire


SAN DIEGO
, Nov. 15, 2025 /PRNewswire/ — The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Netflix, Inc. (NASDAQ: NFLX).

If you have information that could assist in the Netflix investigation or if you are a Netflix investor who suffered a loss and would like to learn more, you can provide your information here:


https://www.rgrdlaw.com/cases-netflix-inc-investigation-nflx.html/

You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected].

THE COMPANY: Netflix provides entertainment services with over 300 million paid memberships in over 190 countries enjoying.

THE INVESTIGATION: Robbins Geller is investigating whether Netflix and certain of its executives made materially false and/or misleading statements and/or omitted material information regarding Netflix business and operations.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:


https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices. 

Contact:

Robbins Geller Rudman & Dowd LLP
J.C. Sanchez, Jennifer N. Caringal
655 W. Broadway, Suite 1900, San Diego, CA 92101
800-449-4900
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nflx-investigation-investigation-launched-into-netflix-inc-attorneys-encourage-investors-and-potential-witnesses-to-contact-law-firm-302615965.html

SOURCE Robbins Geller Rudman & Dowd LLP

Posted on

Important Notice to Long-Term Shareholders of Avantor, Inc. (NYSE: AVTR); enCore Energy Corp. (NASDAQ: EU); Fortrea Holdings, Inc. (NASDAQ: FTRE); and Stride, Inc. (NYSE: LRN): Grabar Law Office Investigates Claims on Your Behalf

PHILADELPHIA, Nov. 15, 2025 (GLOBE NEWSWIRE) —


Avantor, Inc. (NYSE: AVTR):

Grabar Law Office is investigating claims on behalf of shareholders of Avantor, Inc. (NYSE: AVTR). The investigation concerns whether certain officers and directors breached their fiduciary duties.

If you purchased Avantor, Inc. (NYSE: AVTR), shares prior to March 5, 2024, and still hold shares today,
you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.
Please
visit

https://grabarlaw.com/the-latest/avantor-shareholder-investigation/

, contact Joshua Grabar at

[email protected]

, or call 267-507-6085.

WHY? As alleged in a recently filed underlying securities fraud class action complaint, Avantor, Inc. (NYSE: AVTR), through certain of its officers, made materially false and misleading statements materially false and/or misleading statements, as well as failed to disclose material adverse facts, about the Company’s business and operations. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Avantor’s competitive positioning was weaker than Defendants had publicly represented; (2) Avantor was experiencing negative effects from increased competition; and (3) as a result, Defendants’ representations about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

WHAT YOU CAN DO NOW:
If you purchased Avantor, Inc. (NYSE: AVTR)
,
shares prior to
March 5, 2024
and still hold shares today,
you are encouraged to visit

https://grabarlaw.com/the-latest/avantor-shareholder-investigation/

, contact Joshua Grabar at

[email protected]

,
or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $AVTR #Avantor


enCore Energy Corp. (NASDAQ: EU):

Grabar Law Office is investigating claims on behalf of shareholders of enCore Energy Corp. (NASDAQ: EU). The investigation concerns whether certain officers and directors breached their fiduciary duties.

If you purchased enCore Energy Corp. (NASDAQ: EU) shares prior to March 28, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/encore-shareholder-investigation/, contact Joshua Grabar at [email protected], or call 267-507-6085.

WHY? According to an underlying securities fraud class action complaint, enCore Energy Corp. (NASDAQ: EU), through certain of its officers, made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants failed to disclose to investors: (1) that enCore lacked effective internal controls over financial reporting; (2) that enCore could not capitalize certain exploratory and development costs under GAAP; (3) that, as a result, its net losses had substantially increased; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT YOU CAN DO NOW:
If you purchased enCore Energy Corp. (NASDAQ: EU) shares prior to
March 28, 2024,
and still hold shares today,
you are encouraged to

https://grabarlaw.com/the-latest/encore-shareholder-investigation/

, contact Joshua Grabar at

[email protected]

,
or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.   $EU #encoreenergy


Fortrea Holdings, Inc. (NASDAQ: FTRE)

:

Grabar Law Office is investigating claims on behalf of shareholders of Fortrea Holdings, Inc. (NASDAQ: FTRE). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

Current Fortrea Holdings, Inc. (NASDAQ: FTRE) shareholders who shares prior to
July 3, 2023
and still hold shares today,
can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever.

You are encouraged to visit

https://grabarlaw.com/the-latest/fortrea-shareholder-investigation/

, contact Joshua Grabar at

[email protected]

,
or call 267-507-6085.

WHY? According to an underlying securities fraud class action complaint, Fortrea Holdings, Inc. (NASDAQ: FTRE), through certain of its officers, made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company’s 2025 earnings; (ii) Fortrea overstated the cost savings it would likely achieve by exiting the TSAs; (iii) as a result, the Company’s previously announced EBITDA targets for 2025 were inflated; (iv) accordingly, the viability of the Company’s post-Spin-Off business model, as well as its business and/or financial prospects, were overstated; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

WHAT YOU CAN DO NOW:
If you purchased Fortrea Holdings, Inc. (NASDAQ: FTRE) shares prior to
July 3, 2023
and still hold shares today,
you are encouraged to visit

https://grabarlaw.com/the-latest/fortrea-shareholder-investigation/

, contact Joshua Grabar at

[email protected]

,
or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.   $FTRE #Fortrea


Stride, Inc. (NYSE: LRN):

Grabar Law Office is investigating claims on behalf of shareholders of Stride, Inc. (NYSE: LRN). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Stride, Inc. (NYSE: LRN) shares prior to
July 3, 2023,
and still hold shares today, you
can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit

https://grabarlaw.com/the-latest/stride-shareholder-investigation/

, contact Joshua Grabar at

[email protected]

,
or call 267-507-6085.

WHY? According to an underlying securities fraud class action complaint, Stride, Inc. (NYSE: LRN), through certain of its officers, made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (1) inflating enrollment numbers by retaining “ghost students”; (2) cutting staffing costs by assigning teachers’ caseloads far beyond the required statutory limits; (3) ignoring compliance requirements, including background checks and licensure laws for its employees, and ignoring federally mandated special education services to students; (4) suppressing whistleblowers who documented financial directives from Stride’s leadership to delay hiring and deny services to preserve profit margins; and (5) losing existing and potential enrollments.

WHAT YOU CAN DO NOW:
If you purchased Stride, Inc. (NYSE: LRN) shares prior to
July 3, 2023,
and still hold shares today,
you are encouraged to visit

https://grabarlaw.com/the-latest/stride-shareholder-investigation/

, contact Joshua Grabar at

[email protected]

,
or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.   $LRN #Stride

Attorney Advertising Disclaimer

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel:  267-507-6085
Email: [email protected]



Posted on

STOCK ALERT: Stride, Inc. (LRN) Investors may be Eligible for Compensation in Securities Class Action – Contact BFA Law by January 12 Deadline

NEW YORK, Nov. 15, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Stride, Inc. (NYSE: LRN) and certain of the Company’s senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws.

If you invested in Stride, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/stride-inc-class-action-lawsuit.

Investors have until January 12, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Stride securities. The case is pending in the U.S. District Court for the Eastern District of Virginia and is captioned MacMahon v. Stride, Inc., et al., No. 1:25-cv- 02019.

Why is Stride Being Sued For Securities Fraud?

Stride is an education technology company that provides an online platform to students throughout the U.S. During the relevant period, Stride stated it was seeing “increasing growth in our business,” “in-year strength in demand” for its products and services, and that its customers and potential customers “continue to choose us in record numbers.”

As alleged, in truth, Stride had inflated enrollment numbers by retaining “ghost students,” ignored compliance requirements for its employees, and had “poor customer experience” that resulted in “higher withdrawal rates,” “lower conversion rates,” and had driven students away.

Why did Stride’s Stock Drop?

On September 14, 2025, a report stated that a complaint had been filed against Stride for fraud, deceptive trade practices, systemic violations of law, and intentional and tortious misconduct. It claimed Stride inflated enrollment numbers by retaining “ghost students” on rolls to secure state funding and ignored compliance requirements, including background checks and licensure laws for its employees. This news caused the price of Stride stock to drop $18.60 per share, or more than 11%, from a closing price of $158.36 per share on September 12, 2025, to $139.76 per share on September 15, 2025.

Then, on October 28, 2025, Stride admitted that “poor customer experience” resulted in “higher withdrawal rates,” “lower conversion rates,” and drove students away. Stride estimated the impact caused approximately 10,000-15,000 fewer enrollments and stated that, because of this, its outlook is “muted” compared to prior years. This news caused the price of Stride stock to drop $83.48 per share, or more than 54%, from a closing price of $153.53 per share on October 28, 2025, to $70.05 per share on October 29, 2025.

Click here for more information:

https://www.bfalaw.com/cases/stride-inc-class-action-lawsuit

.

What Can You Do?

If you invested in Stride you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases/stride-inc-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases/stride-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.



Posted on

STOCK ALERT: CarMax, Inc. (KMX) Investors may be Eligible for Compensation in Securities Class Action – Contact BFA Law by January 2 Deadline

NEW YORK, Nov. 15, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against CarMax, Inc. (NYSE: KMX) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in CarMax, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/carmax-inc-class-action-lawsuit.

Investors have until January 2, 2026, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in CarMax securities. The case is pending in the U.S. District Court for the District of Maryland and is captioned Jason Cap v. CarMax, Inc., et al., No. 1:25-cv-03602.

Why is CarMax Being Sued For Securities Fraud?

CarMax sells used cars. During the relevant period, the Company touted the strong and sustainable demand for its cars, driven by factors such as a seamless customer experience.

As alleged, in truth, it appears that the announcement of U.S. tariffs imposed on cars provided a short-term boost to demand, as customers purchased cars prior to the tariffs taking effect.

BFA Law is also investigating the unexpected departure of CEO Bill Nash on November 6, 2025, and whether CarMax properly assessed or reserved for its portfolio of car loans.

Why did CarMax’s Stock Drop?

On September 25, 2025, the Company reported disappointing financial results for the second quarter of its fiscal year 2026. Specifically, CarMax announced sales declines across the board, including a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units. The Company also posted a disappointing second quarter net income of about $95.4 million, down from $132.8 million over the prior year. A main reason for the declines, according to CarMax, was a “pull forward” in demand into the first fiscal quarter due to the announcement of tariffs.

On this news, the price of CarMax stock dropped $11.45 per share, or roughly 20%, from $57.05 per share on September 24, 2025, to $45.60 per share on September 25, 2025.

Then, on November 6, 2025, CarMax announced the unexpected departure of CEO Bill Nash and a weak preliminary Q3 2025 outlook. On this news, the price of CarMax stock dropped over 24%.

Click here for more information:

https://www.bfalaw.com/cases/carmax-inc-class-action-lawsuit

.

What Can You Do?

If you invested in CarMax you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases/carmax-inc-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases/carmax-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.



Posted on

STOCK ALERT: MoonLake Immunotherapeutics (MLTX) Investors may be Eligible for Compensation in Securities Class Action – Contact BFA Law by December 15 Deadline

NEW YORK, Nov. 15, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit.

Investors have until December 15, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in MoonLake common stock. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612.

Why Was MoonLake Sued for Securities Fraud?

MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases. During the relevant period, MoonLake conducted highly anticipated Phase 3 VELA trials for sonelokimab (“SLK”), an investigational therapeutic designed to treat adult participants with moderate to severe hidradenitis suppurativa (“HS”).

MoonLake told investors that its “strong clinical data,” including results from its Phase 2 MIRA trial, translate into “higher clinical responses for patients, and provide ample opportunity for differentiation of sonelokimab versus all competitors.” The Company also stated that SLK’s Nanobody structure differed in beneficial ways from traditional monoclonal antibody treatments from its competitors.

As alleged, in truth, the Company’s clinical data and Nanobody structure did not confer a superior clinical benefit over its competitors, calling into question the drug’s chances for regulatory approval and commercial viability.

The Stock Declines as the Truth Is Revealed

On September 28, 2025, MoonLake reported its week 16 results of the VELA Phase 3 trials. The Company reported disappointing results for both trials, with VELA-2 failing to meet its primary endpoint, calling into question the drug’s chances for regulatory approval and commercial viability. On this news, the price of MoonLake stock fell $55.75 per share, or nearly 90%, from $61.99 per share on September 26, 2025, to $6.24 per share on September 29, 2025, the following trading day.

Click here for more information:

https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit

.

What Can You Do?

If you invested in MoonLake you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.



Posted on

STOCK ALERT: Ardent Health, Inc. (ARDT) Investors may be Eligible for Compensation – Contact BFA Law about its Securities Investigation

NEW YORK, Nov. 15, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Ardent Health, Inc. (NYSE: ARDT) for potential violations of the federal securities laws.

If you invested in Ardent, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ardent-health-inc-class-action-investigation.

Why Is Ardent being Investigated for Securities Violations?

Ardent is a provider of healthcare in mid-sized urban communities across the U.S. The Company operates a network of hospitals, ambulatory facilities, and physician practices. During the relevant period, it appears that Ardent improperly accounted for its accounts receivable and professional liability reserves.

Why Did Ardent’s Stock Drop?

On November 12, 2025, Ardent reported its Q3 2025 financial results. The Company revealed it had completed “hindsight evaluations of historical collection trends” that resulted in a $43 million decrease in revenue for the quarter. Ardent also revealed that it increased its professional liability reserves by $54 million because of “adverse prior period claim developments” resulting from a set of claims between 2019 and 2022 “as well as consideration of broader industry trends.” On this news, the price of Ardent stock dropped over 33% during the course of trading on November 13, 2025.

Click here for more information:

https://www.bfalaw.com/cases/ardent-health-inc-class-action-investigation

.

What Can You Do?

If you invested in Ardent you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases/ardent-health-inc-class-action-investigation

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases/ardent-health-inc-class-action-investigation

Attorney advertising. Past results do not guarantee future outcomes.



Posted on

STOCK ALERT: Beyond Meat, Inc. (BYND) Investors may be Eligible for Compensation – Contact BFA Law about its Securities Fraud Investigation

NEW YORK, Nov. 15, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Beyond Meat, Inc. (NASDAQ: BYND) for potential violations of the federal securities laws.

If you invested in Beyond Meat, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/beyond-meat-inc-class-action-investigation.

Why Is Beyond Meat Being Investigated for Securities Fraud?

Beyond Meat makes plant-based meat alternatives. In late 2023, the company went through a global operations review and depreciated certain long-lived assets. Beyond Meat said that these assets were recorded in assets held for sale in its consolidated balance sheet at the lower of their carrying value or fair value less costs to sell, and that there were no impairments. 

BFA is investigating whether Beyond Meat inflated the value of certain long-lived assets.

Why Did Beyond Meat’s Stock Drop?

On October 24, 2025, Beyond Meat announced that it “expects to record a non-cash impairment charge for the three months ended September 27, 2025, related to certain of its long-lived assets,” which it “expected to be material.” On this news, the price of Beyond Meat stock dropped roughly 23%, from $2.84 per share on October 23, 2025 to $2.185 per share on October 24, 2025.

Then, on November 3, 2025, the company delayed its earnings announcement for 3Q 25 as it needed more time to complete the impairment review. This news caused Beyond Meat stock to decline substantially during the trading day on November 3, 2025.

Click here for more information:

https://www.bfalaw.com/cases/beyond-meat-inc-class-action-investigation

.

What Can You Do?

If you invested in Beyond Meat you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases/beyond-meat-inc-class-action-investigation

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases/beyond-meat-inc-class-action-investigation

Attorney advertising. Past results do not guarantee future outcomes.



Posted on

STOCK ALERT: Synopsys, Inc. (SNPS) Investors may be Eligible for Compensation in Securities Class Action – Contact BFA Law by December 30 Deadline

NEW YORK, Nov. 15, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Synopsys, Inc. (NASDAQ: SNPS) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in Synopsys, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit.

Investors have until December 30, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Synopsys securities. The class action is pending in the U.S. District Court for the Northern District of California and is captioned Kim v. Synopsys, Inc., et al., No. 3:25-cv-09410.

Why Was Synopsys Sued for Securities Fraud?

Synopsys provides design automation software products used to design and test integrated circuits. The Company’s Design IP segment, which provides pre-designed silicon components to semiconductor companies, has been the Company’s fastest-growing segment, growing from 25% of its revenue in 2022, to 31% in 2024.

During the relevant period, Synopsys told investors that its customers “rely on Synopsys IP to minimize integration risk and speed time to market” and that it was seeing “strength in Europe and South Korea.” Synopsys also stated it was “continuing to develop and deploy[] AI into our products and the operations of our business.”

As alleged, in truth, the Company’s Design IP customers began to require additional customization for IP components, which was deteriorating the economics of its Design IP business and jeopardizing its business model.

The Stock Declines as the Truth Is Revealed

On September 9, 2025, Synopsys released its Q3 2025 financial results, revealing its “IP business underperformed expectations.” The Company reported revenue for its Design IP segment of $425.9 million, a 7.7% decline year-over-year and net income of $242.5 million, a 43% year-over-year decline. The Company revealed that its Design IP customers require “more and more customization,” which “takes longer” and requires “more resources.” As a result, the Company stated it was having “an ongoing dialogue with our customers” regarding changing its business model. This news caused the price of Synopsys stock to fall $217.59 per share, or nearly 36%, from $604.37 per share on September 9, 2025, to $387.78 per share on September 10, 2025.

Click here for more information:

https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit

.

What Can You Do?

If you invested in Synopsys you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases/synopsys-inc-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.



Posted on

STOCK ALERT: James Hardie Industries plc (JHX) Investors may be Eligible for Compensation in Securities Class Action – Contact BFA Law by December 23 Deadline

NEW YORK, Nov. 15, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against James Hardie Industries plc (NYSE: JHX) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.

If you invested in James Hardie, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit.

Investors have until December 23, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in James Hardie common stock (formerly American Depositary Shares). The class action is pending in the U.S. District Court for the Northern District of Illinois and is captioned Laborers’ District Council and Contractors’ Pension Fund of Ohio v. James Hardie Industries plc, et al., No. 1:25-cv-13018.

Why Was James Hardie Sued for Securities Fraud?

James Hardie is a producer and marketer of high-performance fiber cement building solutions. The largest application for the Company’s fiber cement building products in the United Stated and Canada is in external siding for the residential building industry.

During the relevant period, James Hardie told investors that the results of its North American fiber cement segment demonstrated its “inherent strength” and “the underlying momentum in our strategy.” The Company also stated on May 20, 2025, that it was seeing “normal stock levels” among its customers and that it was “seeing performance in the month to date as we would expect.”

As alleged, in truth, the Company’s North American sales during the relevant period were the result of inventory loading by channel partners, with the hallmarks of fraudulent channel stuffing, not sustainable customer demand as represented.

The Stock Declines as the Truth Is Revealed

On August 19, 2025, James Hardie revealed that its North American fiber cement sales declined 12% during the quarter, driven by destocking first discovered “in April through May” as customers “made efforts to return to more normal inventory levels[.]” The Company also revealed that significant inventory destocking was expected to continue to impact sales for the next several quarters. On this news, the price of James Hardie stock fell $9.79 per share, or more than 34%, from $28.43 per share on August 19, 2025, to $18.64 per share on August 20, 2025.

Click here for more information:

https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit

.

What Can You Do?

If you invested in James Hardie you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:


https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.


https://www.bfalaw.com/cases/james-hardie-industries-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.